Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
6,100 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Herrera AF, LeBlanc M, Castellino SM, et al. · N Engl J Med · 2024Multicenter Study, Randomized Controlled Trial
- Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.
Rutherford SC, Li H, Herrera AF, et al. · J Clin Oncol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, et al. · J Clin Oncol · 2023Randomized Controlled Trial, Multicenter Study
- Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
Ansell SM, Radford J, Connors JM, et al. · N Engl J Med · 2022Comparative Study, Randomized Controlled Trial
- Hodgkin Lymphoma in Adults.
Bröckelmann PJ, Eichenauer DA, Jakob T, et al. · Dtsch Arztebl Int · 2018Systematic Review
- Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Moskowitz CH, Walewski J, Nademanee A, et al. · Blood · 2018Clinical Trial, Phase III, Multicenter Study
- Hodgkin's lymphoma.
Rahemtulla A, Terpos E · BMJ Clin Evid · 2009Systematic Review
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, et al. · Lancet · 2015Clinical Trial, Phase III, Multicenter Study
- CT of lymphoma: spectrum of disease.
Fishman EK, Kuhlman JE, Jones RJ · Radiographics · 1991Research Support, Non-U.S. Gov't, Systematic Review
- Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis.
Wu PC, Huang IH, Liu CW, et al. · J Dtsch Dermatol Ges · 2021Meta-Analysis, Systematic Review
- Presentation of B-cell lymphoma in childhood and adolescence: a systematic review and meta-analysis.
Saatci D, Zhu C, Harnden A, et al. · BMC Cancer · 2024Systematic Review, Meta-Analysis
- Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
Dada R, Zekri J, Al Saadi R · Expert Opin Biol Ther · 2016Meta-Analysis, Systematic Review
- Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826).
Ahmed S, Li H, Herrera AF, et al. · Blood Adv · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma.
Williams AM, Rodday AM, Renfro LA, et al. · J Natl Cancer Inst · 2025Clinical Trial, Phase III, Multicenter Study
- Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers.
Chang ET, Delzell E · J Environ Sci Health B · 2016Meta-Analysis, Research Support, Non-U.S. Gov't
- Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ, Nievelstein RA, Kwee TC · Br J Haematol · 2015Meta-Analysis, Research Support, Non-U.S. Gov't
- Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.
Guo B, Cen H, Tan X, et al. · BMC Med · 2016Meta-Analysis
- Prognostic value of Bcl2 and p53 in Hodgkin lymphoma: A systematic review and meta-analysis.
Travaglino A, Russo D, Varricchio S, et al. · Pathol Res Pract · 2021Meta-Analysis, Systematic Review
- Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis.
Mullen CJR, Volesky KD, Greenwald ZR, et al. · Cancer Epidemiol Biomarkers Prev · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
- PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis.
Sickinger MT, von Tresckow B, Kobe C, et al. · Crit Rev Oncol Hematol · 2016Meta-Analysis, Systematic Review
- Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
Arabloo J, Azari S, Gorji HA, et al. · Eur J Clin Pharmacol · 2023Systematic Review
- Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy.
Adams HJA, Nievelstein RAJ, Kwee TC · Ann Hematol · 2016Meta-Analysis, Research Support, Non-U.S. Gov't
- Meta-analysis: Risk of lymphoma in patients with inflammatory bowel disease in population-based cohort studies.
Zamani M, Alizadeh-Tabari S, Murad MH, et al. · Aliment Pharmacol Ther · 2024Meta-Analysis, Systematic Review
- Candidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis.
Sud A, Hemminki K, Houlston RS · Hematol Oncol · 2017Meta-Analysis, Systematic Review
- Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.
Rashidi A, Ebadi M, Cashen AF · Bone Marrow Transplant · 2016Meta-Analysis, Research Support, N.I.H., Extramural
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.